Search Results
Sep 11, 2026, 03:00 ET Mayer Brown Adds Ashton and Bates to Leading Capital Markets Practice
are established in various jurisdictions and may be a legal person or a partnership. PK Wong & Nair LLC ("PKWN") is the constituent Singapore law practice of our licensed joint law venture in Singapore, Mayer Brown PK Wong & Nair Pte. Ltd. More information about the individual Mayer Brown Practices
More news about: Mayer Brown
Sep 11, 2026, 03:00 ET Mayer Brown Adds Ashton and Bates to Leading Capital Markets Practice
are established in various jurisdictions and may be a legal person or a partnership. PK Wong & Nair LLC ("PKWN") is the constituent Singapore law practice of our licensed joint law venture in Singapore, Mayer Brown PK Wong & Nair Pte. Ltd. More information about the individual Mayer Brown Practices
More news about: Mayer Brown
Sep 10, 2026, 17:57 ET A Landmark Transformation: The International School of San Francisco Celebrates Its Campus Renovation
largest secular independent school in San Francisco, located in the vibrant Hayes Valley neighborhood. It offers a French bilingual program for learners in PK2 through Grade 8. In high school, students pursue either the prestigious International Baccalaureate or the French Baccalaureate. For more information,
More news about: The International School of San Francisco
Sep 10, 2026, 07:00 ET BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
30 patients with WHO grade 3/4 glioma (≤2 prior therapy lines). Primary endpoints are safety, tolerability, and MTD/RP2D; secondary endpoints include PK, antitumor response, 6-month PFS, and exploratory endpoints include pharmacodynamic markers (P21, TMEM71, 5hmC, 5mC, γH2AX). Four leading US academic
More news about: BioLineRx Ltd.; Hemispherian AS
Sep 08, 2026, 10:06 ET Amino Minder Brings Real Pharmacokinetic Modeling to Peptide and GLP-1 Tracking, Now Live on the Web -- Android App Coming Soon
pharmacokinetic (PK) engine that estimates and graphs a user's plasma level for each tracked compound over time, rather than simply logging that a dose was taken. Most peptide-tracking apps on the market function as digital logbooks — a calendar of doses, reminders, and inventory. Amino Minder's PK engine
More news about: Amino Minder
Sep 07, 2026, 23:56 ET /ĐÍNH CHÍNH -- Wooree Group/
Stability); độ ổn định trong môi trường đường tiêu hóa (Gastrointestinal Stability); và đánh giá sinh khả dụng thông qua dược động học (Pharmacokinetics, PK).Ông Yoon nhấn mạnh: "Trong tương lai, thị trường liposome cần phát triển theo hướng mức độ kiểm chứng khoa học trở thành một yếu tố quyết định
More news about: Wooree Group
Sep 07, 2026, 23:50 ET /C O R R E C T I O N -- Wooree Group/
concentration analysis using NTAEncapsulation efficiencyLong-term shelf stabilityGastrointestinal stabilityPharmacokinetic (PK) evaluation of bioavailability"The liposome market should evolve toward a model where competitiveness is determined by how rigorously
More news about: Wooree Group
Sep 02, 2026, 08:15 ET Staying on Track: The IXL LevelUp Diagnostic Snapshot Lets Districts Keep a Closer Eye on Student Progress
IXLCurrently used by 18 million students and 96 of the top 100 U.S. school districts, IXL is an all-inclusive educational platform providing a comprehensive PK-12 curriculum, instructional resources, actionable analytics and a state-of-the-art assessment suite. Available in more than 120 languages, IXL's end-to-end
More news about: IXL Learning
Sep 02, 2026, 02:54 ET RAVEN2 BUKA PRAREGISTRASI UNTUK FRESH START SERVER "ZERO"
ingin kembali bermain. Dibandingkan server yang telah beroperasi, ZERO mengurangi beban dalam proses perkembangan karakter, tekanan monetisasi, aktivitas PK (Player Killing), hingga persaingan antarpemain. Server ini juga menghadirkan Kristal yang Ditanam, sebuah sistem yang memudahkan pemain untuk mendapatkan
More news about: Netmarble Corporation
Sep 02, 2026, 02:51 ET СЕРВЕР СВЕЖЕГО ЗАПУСКА ZERO ОТ RAVEN2 ТЕПЕРЬ ОТКРЫТ ДЛЯ ПРЕДВАРИТЕЛЬНОЙ РЕГИСТРАЦИИ
сервер свежего запуска, представленный с момента запуска RAVEN2. Разработанный для облегчения бремени развития персонажа, давления монетизации, PK (убийства игроков) и конкурентного стресса по сравнению с существующими серверами, ZERO предлагает более доступную среду как для новых, так и для возвращающихся
More news about: Netmarble Corporation
Sep 02, 2026, 02:50 ET RAVEN2'S FRESH START SERVER "ZERO" NOW OPEN FOR PRE-REGISTRATION
the first fresh start server introduced since the launch of RAVEN2. Designed to ease the burden of character progression, monetization pressure, PK (Player Killing), and competitive stress compared to existing servers, ZERO offers a more accessible environment for both new and returning players.
More news about: Netmarble Corporation
Sep 01, 2026, 18:15 ET Common Threads Expands Digital Training Platform to Bring 23 Years of Nutrition Education Online, Launching September 15th
own facilitators to implement Common Threads licensed curriculum.This strategy builds on what Common Threads has seen in schools. At Don Haskins PK-8 in El Paso, Texas, an initial Cooking Skills & World Cuisine program generated enough demand for the school to extend programming to younger students
More news about: Common Threads
Aug 31, 2026, 10:30 ET Xenograft Model Selection and Standardization Across CDX, PDX, Humanized, and Organoid-Derived Models in Preclinical Cancer Research
most cost-effective platform for early in vivo efficacy, reaching readout in 5–7 weeks with large matched cohorts and interpretable dose-response, PK/PD, and tolerability data. PDX models preserve donor histology, genomic architecture, and intratumoral heterogeneity across early passages, supporting
More news about: Altogen Labs
Aug 31, 2026, 07:00 ET BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
progressive GBM and other high-grade gliomas. The objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy.The Phase 2a expansion part of the trial is planned to include various population cohorts, including GBM (newly
More news about: BioLineRx Ltd.
Aug 26, 2026, 06:37 ET Commercialization Roadmap Validated with Three-digit Million-dollar Revenue: Insilico Medicine Announces Interim Results for the First Half of 2026
In June, ISM8969/HT-001 completed first-in-human dosing in a Phase I clinical trial, which is designed to evaluate the safety, tolerability, PK, and PD profiles.In August, ISM8969/HT-001 was announced to have received IND clearance from China's CDE for the treatment of Parkinson's disease.ISM9682
More news about: Insilico Medicine
Aug 24, 2026, 20:30 ET Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
tolerability of ATG-201 monotherapy and to determine its recommended Phase II dose (RP2D). Secondary objectives include evaluating the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, immunogenicity, preliminary efficacy of ATG-201.Antengene and UCB have entered into an agreement
More news about: Antengene Corporation Limited
Aug 24, 2026, 06:00 ET PK Companies Unites Inspection Services Under PK Technical & Inspection
retention, forming the foundation of the new corporate culture.Part of the PK Companies Family of DivisionsPK Technical & Inspection is part of PK Companies alongside PK Industrial, PK Safety, and intelliSPEC, a family of asset reliability services and technology businesses
More news about: PK Companies
Aug 21, 2026, 08:08 ET CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist
Australia is a randomized, double-blind, placebo-controlled study in healthy participants, designed to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of CG-0416 following single and multiple ascending doses. Leveraging Australia's well-established Phase I clinical infrastructure,
More news about: CureGene
Aug 20, 2026, 04:00 ET Lucid Announces Munsterhuis Autobedrijven as First Retail Partner in the Netherlands
abrufbar unter www.dat.de/co2, verfügbar.NETHERLANDS Lucid Air 325 - 920 kW (442 - 1.251 pk), 694 - 960 km gecombineerde actieradius (WLTP), 0 g CO₂ per gereden km (WLTP), energieverbruik 19,1 - 11,8 kWh/100 km. De actieradius is gebaseerd
More news about: Lucid Group
Aug 20, 2026, 04:00 ET Lucid Announces Munsterhuis Autobedrijven as First Retail Partner in the Netherlands
abrufbar unter www.dat.de/co2, verfügbar.NETHERLANDS Lucid Air 325 - 920 kW (442 - 1.251 pk), 694 - 960 km gecombineerde actieradius (WLTP), 0 g CO₂ per gereden km (WLTP), energieverbruik 19,1 - 11,8 kWh/100 km. De actieradius is gebaseerd
More news about: Lucid Group
Aug 20, 2026, 04:00 ET Lucid gibt Munsterhuis Autobedrijven als ersten Handelspartner in den Niederlanden bekannt
www.dat.de/co2, verfügbar.NETHERLANDSLucid Air 325 - 920 kW (442 - 1.251 pk), 694 - 960 km gecombineerde actieradius (WLTP), 0 g CO₂ per gereden km (WLTP), energieverbruik 19,1 - 11,8 kWh/100 km. De actieradius is gebaseerd
More news about: Lucid Group
Aug 20, 2026, 04:00 ET Lucid annonce Munsterhuis Autobedrijven comme son premier partenaire commercial aux Pays-Bas
abrufbar unter www.dat.de/co2, verfügbar.NETHERLANDS Lucid Air 325 - 920 kW (442 - 1.251 pk), 694 - 960 km gecombineerde actieradius (WLTP), 0 g CO₂ per gereden km (WLTP), energieverbruik 19,1 - 11,8 kWh/100 km. De actieradius is gebaseerd
More news about: Lucid Group
Aug 20, 2026, 04:00 ET Lucid anuncia Munsterhuis Autobedrijven como primer socio minorista en los Países Bajos
abrufbar unter www.dat.de/co2, verfügbar.NETHERLANDSLucid Air 325 - 920 kW (442 - 1.251 pk), 694 - 960 km gecombineerde actieradius (WLTP), 0 g CO₂ per gereden km (WLTP), energieverbruik 19,1 - 11,8 kWh/100 km.De actieradius is gebaseerd
More news about: Lucid Group
Aug 19, 2026, 09:41 ET Sensorium Therapeutics Announces SNTX-2643 Phase 1a Data to Be Presented at Psych Congress 2026
presentation will include results from Sensorium's ongoing Phase 1a study of SNTX-2643 in healthy adults evaluating its safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profile. The study includes single-ascending dose, exploratory qEEG target engagement/pharmacodynamic and food-effect cohorts.
More news about: Sensorium Therapeutics
Aug 19, 2026, 09:30 ET Louisiana Department of Education's Former Communications Chief Joins Award Winning Education PR Firm
navigating high-stakes state education policy, Dunn will support strategic communications, media relations, and public affairs efforts across the firm's PK-12 and postsecondary portfolio. Dunn previously served as press secretary and director of communications for the Louisiana Department of Education,
More news about: Whiteboard Advisors